| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 113 | 113 |
| Net decrease in cash, cash equivalents and restricted cash | -3,771 | 6,811 |
| Cash and cash equivalents at beginning of period | 28,648 | - |
| Cash and cash equivalents at end of period | 24,877 | - |
Nautilus Biotechnology, Inc. (NAUT)
Nautilus Biotechnology, Inc. (NAUT)